Abstract: An electrolyte composition is described. The electrolyte composition includes at least one ionic compound; at least one polar solvent; at least one polymerizable material; at least one nanoparticle based viscosity modifier; at least one chain transfer agent; and at least one initiator. Also described are electrochromic articles and devices including an electrolyte layer including an electrolyte composition. Methods of assembling an electrochromic article are also included.

Abstract: An electrode is described. The electrode includes a substrate having a first and a second surface, a conductive layer, multilayer structure having alternating layers of at least one polymer layer and at least one electroactive chemical bound nanoparticle layer. The conductive layer is disposed on the second surface of the substrate, and the multilayer structure is disposed on the conductive layer.

Abstract: The present teachings relate to compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, R4, X, and Y are as defined herein. The present teachings also provide methods of making the compounds of formula I and methods of inhibiting matrix metalloproteinases, in particular, MMP-12, that may be involved in pathological disorders found in mammals, including a human.

Abstract: An electrode is described. The electrode includes a substrate having a first and a second surface, a conductive layer, multilayer structure having alternating layers of at least one polymer layer and at least one electroactive chemical bound nanoparticle layer. The conductive layer is disposed on the second surface of the substrate, and the multilayer structure is disposed on the conductive layer.

Abstract: A composition of VSD material comprises a binder, and one or more types of particles that include a concentration of doped semiconductor particles.

Abstract: A composition of voltage switchable dielectric (VSD) material that comprises a concentration of core shell particles that individually comprise an insulative core and one or more shell layers.

Abstract: A composition of voltage switchable dielectric (VSD) material that comprises a concentration of core shelled particles that individually comprise a conductor core and a conductor shell, so as to form a conductor-on-conductor core shell particle constituent for the VSD material.

Abstract: A composition of voltage switchable dielectric (VSD) material that comprises a concentration of core shelled particles that individually comprise a conductor core and a shell, the shell of each core shelled particle being (i) multilayered, and/or (ii) heterogeneous.

Abstract: A composition is provided that includes a polymer binder, and one or more classes of particle constituents. At least one class of particle constituents includes semiconductive particles that individually have a band gap that is no greater than 2 eV. As VSD material, the composition is (i) dielectric in absence of a voltage that exceeds a characteristic voltage level, and (ii) conductive with application of said voltage that exceeds the characteristic voltage level.

Abstract: Embodiments described herein provide for VSD material that has superior characteristics for its use as an integral structural component of a device.

Abstract: Embodiments described herein provide for a composition of voltage switchable dielectric (VSD) material that includes a concentration of modified high-aspect ratio (HAR) particles. In an embodiment, at least a portion of the concentration includes HAR particles are surface-modified to provide core-shell HAR particles. As an alternative or addition, a portion of the concentration includes HAR particles that are surface-modified to have activated surfaces.

Abstract: The present invention provides an azolylacylquanidine compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.

Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-? expression utilizing compounds of the present invention are also disclosed.

Abstract: The present invention provides an azolylacylquanidine compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.

Abstract: An electrolyte composition is described. The electrolyte composition includes at least one ionic compound; at least one polar solvent; at least one polymerizable material; at least one nanoparticle based viscosity modifier; at least one chain transfer agent; and at least one initiator. Also described are electrochromic articles and devices including an electrolyte layer including an electrolyte composition. Methods of assembling an electrochromic article are also included.

Abstract: A nanoparticle thin film is described. An article includes a substrate and the nanoparticle thin film that includes nanoparticles having an average size from 5 nm to 50 nm, at least one electroactive chemical, and at least one organic binder material. The electroactive chemical binds to the surface of the nanoparticles. Also described are dispersions and coating compositions.

Abstract: An electrode is described. The electrode includes a substrate having a first and a second surface, a conductive layer, multilayer structure having alternating layers of at least one polymer layer and at least one electroactive chemical bound nanoparticle layer. The conductive layer is disposed on the second surface of the substrate, and the multilayer structure is disposed on the conductive layer.

Abstract: An electrode is described. The electrode has a substrate having a first and a second surface; a conductive layer; an electroactive layer that includes nanoparticles having an average size from 5 nm to 30 nm; at least one electroactive chemical and at least one organic binder material. The electroactive chemical binds to the surface of the nanoparticles. The conductive layer is disposed on the second surface of the substrate, and the electroactive layer is disposed on the conductive layer. Also described are electrochromic articles including the electrode, and a coating composition that can be utilized to fabricate the electrode.

Abstract: The present invention provides compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective amount of a compound of formula (I) to the mammal.

Abstract: An optical waveguide comprises a core, an inner cladding laterally surrounding the core, and an outer cladding laterally surrounding the inner cladding, wherein the core, inner cladding, and outer cladding have a depressed well configuration. The waveguide operates in three or more wavelength bands, wherein a first wavelength band is centered at about 1300 nm, and wherein a second wavelength band is centered at about 1625 nm. The waveguide has bend losses that are less than or equal to 1.0 dB/turn when measured on a 5 mm radius bend at 1625 nm and bend losses that are less than or equal to 1.5 dB/turn when measured on a 5 mm radius bend at 1650 nm.